Shigeki Mitsuoka

EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib

Naruo Yoshimura, Shinzoh Kudoh, Tatsuo Kimura et al. · Lung Cancer · 2005 · 81 citations

Medicine, Receptor Tyrosine Kinase, Pathology +7

Efficacy and safety of ultrasound (US) guided percutaneous needle biopsy for peripheral lung or pleural lesion: comparison with computed tomography (CT) guided needle biopsy

Norio Yamamoto, Tetsuya Watanabe, Kazuhiro Yamada et al. · Journal of Thoracic Disease · 2019 · 70 citations · Full text

Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation

Naruo Yoshimura, Shinzoh Kudoh, Shigeki Mitsuoka et al. · Lung Cancer · 2015 · 51 citations

Sensitive Egfr Mutation, Medicine, Combination Regimen +7

Prospective Assessment of Continuation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Pemetrexed

Naruo Yoshimura, Kyoichi Okishio, Shigeki Mitsuoka et al. · Journal of Thoracic Oncology · 2012 · 48 citations · Full text

Urology, Acquired Resistance, Medicine +6

Differences in molecular epidemiology of lung cancer among ethnicities (Asian vs. Caucasian)

Motohiro Izumi, Tomohiro Suzumura, Koichi Ogawa et al. · Journal of Thoracic Disease · 2020 · 46 citations · Full text